Inhibikase Therapeutics Inc — Bilancio Trimestrale (NASDAQ:IKT) | MetaTrader

Apri il grafico completo

Notizie

H.C. Wainwright conferma il rating su Inhibikase per i progressi dello studio

Inhibikase arruola il primo paziente nello studio di Fase 3 per farmaco PAH

BofA Securities avvia copertura su Inhibikase con rating Buy

BofA Securities initiates coverage on Inhibikase stock with Buy rating

Jefferies riconferma il rating Buy su Inhibikase, citando un percorso FDA più rapido

Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path

H.C. Wainwright avvia copertura su Inhibikase con rating Buy

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating

Monday’s Insider Activity: Top Executives Trade Shares at Tech Giants

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Gap (NYSE:GAP), Elastic (NYSE:ESTC)

Inhibikase Therapeutics fissa il prezzo dell’offerta pubblica a 100 milioni di dollari

Inhibikase Therapeutics prices $100 million public offering